Trichomegaly induced by erlotinib

Orbit

Volumn 27, Issue 4, 2008, Pages 329-330

  Papadopoulos, Rebecca ^a   Chasapi, Vasiliki ^b   Bachariou, Alexandre ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b ANDREAS SYGROS HOSPITAL   (Greece)

Author keywords

Erlotinib; Eyelashes; Trichomegaly

Indexed keywords

ERLOTINIB; LATANOPROST; PLATINUM COMPLEX;

AGED; ANAMNESIS; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CASE REPORT; DIARRHEA; DRUG DOSE REDUCTION; EYELASH; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; OPEN ANGLE GLAUCOMA; RASH; TREATMENT RESPONSE; TRICHIASIS; TRICHOMEGALY; TUMOR VOLUME;

ADENOCARCINOMA; AGED; BONE NEOPLASMS; EYELASHES; FEMALE; HUMANS; HYPERTRICHOSIS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 50049106557     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.1080/01676830802222936     Document Type: Article

References (6)

1. Bouche O, Brixi-Benmansour H, Bertin A, et el. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol. 2005; 16:1711-1712.
2. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 2006; 1:1040-1041.
3. Lane K, Goldstein SM. Erlotinib associated trichomegaly. Ophthal Plast Reconstr Surg. 2007; 23(1):65-66.
4. Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg. 2007; 23(1):63-65.
5. Segaert S, Van Cutsem E, Clinical signs, pathophysiology, and management of skin toxicity during therapy with epidermal growth factor receptor inhibitor. Ann Oncol. 2005; 16:1425-1433.
6. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva®) and gefitinib (Iressa®). Oncologist. 2005; 10:579-589.